US 12,304,911 B2
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
Nicole Harriott, San Diego, CA (US); Nicholas Pagano, San Diego, CA (US); and Byron A. Boon, San Diego, CA (US)
Assigned to Neurocrine Biosciences, Inc., San Diego, CA (US)
Filed by Neurocrine Biosciences, Inc., San Diego, CA (US)
Filed on Jun. 9, 2023, as Appl. No. 18/207,807.
Application 18/207,807 is a continuation of application No. 18/096,073, filed on Jan. 12, 2023, granted, now 11,718,618.
Application 18/096,073 is a continuation of application No. PCT/US2022/021080, filed on Mar. 21, 2022.
Claims priority of provisional application 63/164,135, filed on Mar. 22, 2021.
Prior Publication US 2024/0010647 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/14 (2006.01); A61P 25/18 (2006.01); C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 25/18 (2018.01)] 21 Claims
 
1. A method for treating a neurological disease, a neurological disorder, a psychiatric disease, or a psychiatric disorder in a subject in need thereof, wherein the method comprises administering to the subject a compound of Formula (Ia):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is:

OG Complex Work Unit Chemistry
wherein the neurological disease, the neurological disorder, the psychiatric disease, or the psychiatric disorder is selected from the group consisting of:
schizophrenia and schizoaffective disorder.